4-[(1S,2R)-2-(4-aminophenyl)cyclopropyl]aniline | 1422041-07-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 4-[(1S,2R)-2-(4-aminophenyl)cyclopropyl]aniline
• CAS: 1422041-07-3
• 化学式: C₁₅H₁₆N₂
• 分子量: 224.305
• InChiKey: LGKULAMDUVWIAV-GASCZTMLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  BOC-L-脯氨酸 、 4-[(1S,2R)-2-(4-aminophenyl)cyclopropyl]aniline 在 盐酸 、 2-乙氧基-1-乙氧碳酰基-1,2-二氢喹啉 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 生成 (2S)-1-(2-phenylacetyl)-N-[4-[(1S,2R)-2-[4-[[(2S)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]phenyl]cyclopropyl]phenyl]pyrrolidine-2-carboxamide
  参考文献：
  名称：

  HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies

  摘要：

  In a recent disclosure,(1) we described the discovery of dimeric, prolinamide-based NS5A replication complex inhibitors exhibiting excellent potency towards an HCV genotype 1b replicon. That disclosure dealt with the SAR exploration of the peripheral region of our lead chemotype, and herein is described the SAR uncovered from a complementary effort that focused on the central core region. From this effort, the contribution of the core region to the overall topology of the pharmacophore, primarily vector orientation and planarity, was determined, with a set of analogs exhibiting < 10 nM EC50 in a genotype 1b replicon assay. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.086
• 作为产物：
  描述：

  (顺式)-1,1'-(1,2-环丙烷二基)二苯 在 tris-(dibenzylideneacetone)dipalladium(0) 、 N-溴代丁二酰亚胺(NBS) 、 lithium hexamethyldisilazane 、 2-(二环己基膦基)联苯 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 生成 4-[(1S,2R)-2-(4-aminophenyl)cyclopropyl]aniline
  参考文献：
  名称：

  HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies

  摘要：

  In a recent disclosure,(1) we described the discovery of dimeric, prolinamide-based NS5A replication complex inhibitors exhibiting excellent potency towards an HCV genotype 1b replicon. That disclosure dealt with the SAR exploration of the peripheral region of our lead chemotype, and herein is described the SAR uncovered from a complementary effort that focused on the central core region. From this effort, the contribution of the core region to the overall topology of the pharmacophore, primarily vector orientation and planarity, was determined, with a set of analogs exhibiting < 10 nM EC50 in a genotype 1b replicon assay. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.086

文献信息

• HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies
  作者：Omar D. Lopez、Van N. Nguyen、Denis R. St. Laurent、Makonen Belema、Michael H. Serrano-Wu、Jason T. Goodrich、Fukang Yang、Yuping Qiu、Amy S. Ripka、Peter T. Nower、Lourdes Valera、Mengping Liu、Donald R. O’Boyle、Jin-Hua Sun、Robert A. Fridell、Julie A. Lemm、Min Gao、Andrew C. Good、Nicholas A. Meanwell、Lawrence B. Snyder

  DOI：10.1016/j.bmcl.2012.11.086

  日期：2013.2

  In a recent disclosure,(1) we described the discovery of dimeric, prolinamide-based NS5A replication complex inhibitors exhibiting excellent potency towards an HCV genotype 1b replicon. That disclosure dealt with the SAR exploration of the peripheral region of our lead chemotype, and herein is described the SAR uncovered from a complementary effort that focused on the central core region. From this effort, the contribution of the core region to the overall topology of the pharmacophore, primarily vector orientation and planarity, was determined, with a set of analogs exhibiting < 10 nM EC50 in a genotype 1b replicon assay. (c) 2012 Elsevier Ltd. All rights reserved.